Death Excess Gives Pause To Merck & Co Keytruda MM Phase III Studies
Executive Summary
Merck & Co has put the brakes on enrolment into two Phase III trials of Keytruda in multiple myeloma to allow it to investigate more deaths in the groups receiving the anti-PD1 product.
You may also be interested in...
Deciphering US FDA’s Keytruda Safety Announcement
Safety notice for Merck's Keytruda in multiple myeloma had some notable elements – from what comes next to who delivered the message.
Merck & Co. Strengthening Its Strong Position In Immuno-Oncology
Additional data presented at ASCO support earlier use of Keytruda in key settings like first-line lung and bladder cancers and approval in new indications like triple-negative breast and gastric cancers. Competitor setbacks also clear the stage for Merck.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.